Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00320021
Status:
COMPLETED
Last Update Posted:
2006-04-27
First Post:
2006-04-27
Brief Title:
Effect of Pyridorin in Patients With Diabetic Nephropathy
Sponsor:
BioStratum
Organization:
BioStratum
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Escalating Dose Pilot Study to Evaluate the Safety Tolerability and Biologic Activity of Pyridorin Pyridoxamine Dihydrochloride in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2006-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to evaluate the safety tolerability and efficacy of Pyridorin pyridoxamine dihydrochloride up to 250 mg given orally twice daily in patients with diabetic kidney disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| PYR-207 | None | None | None |
| PYR-205 | None | None | None |